Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
alector股價下跌,因公司發佈了未達到主要終點的INVOKE-2第2階段試驗結果。此外,美國銀行將股票評級從中立下調至表現不佳。
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Alector股票在公司發佈其未能達到主要終點的INVOKE-2第二階段試驗結果後交易下跌。同時,美國銀行將該股票從中立下調至表現不佳。